A novel blood test has been developed to enhance the early detection of gallbladder cancer, a malignancy that often eludes diagnosis until advanced stages due to subtle initial symptoms. This innovative approach employs liquid biopsy techniques to identify circulating tumor DNA (ctDNA) in the bloodstream, offering a non-invasive alternative to traditional tissue biopsies. By analyzing ctDNA, the test can detect specific genetic mutations associated with gallbladder cancer, potentially facilitating earlier diagnosis and improved patient outcomes.
The integration of such liquid biopsy methods represents a significant advancement in cancer diagnostics. These tests can detect changes in tumor burden months or years before conventional imaging tests can, making them suitable for early tumor detection, monitoring, and detection of resistance mutations. Click for More Details
